- Home
- PCSA vs NDRA Comparison
PCSA vs NDRA Comparison
Compare PCSA & NDRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCSA
- NDRA
- Stock Information
- Founded
- PCSA 2011
- NDRA 2007
- Country
- PCSA United States
- NDRA United States
- Employees
- PCSA N/A
- NDRA N/A
- Industry
- PCSA Biotechnology: Pharmaceutical Preparations
- NDRA Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- PCSA Health Care
- NDRA Health Care
- Exchange
- PCSA Nasdaq
- NDRA Nasdaq
- Market Cap
- PCSA 3.3M
- NDRA 3.1M
- IPO Year
- PCSA N/A
- NDRA 2017
- Fundamental
- Price
- PCSA $0.18
- NDRA $4.17
- Analyst Decision
- PCSA Strong Buy
- NDRA Strong Buy
- Analyst Count
- PCSA 1
- NDRA 1
- Target Price
- PCSA $1.00
- NDRA $46.00
- AVG Volume (30 Days)
- PCSA 2.8M
- NDRA 58.5K
- Earning Date
- PCSA 10-29-2025
- NDRA 08-14-2025
- Dividend Yield
- PCSA N/A
- NDRA N/A
- EPS Growth
- PCSA N/A
- NDRA N/A
- EPS
- PCSA N/A
- NDRA N/A
- Revenue
- PCSA N/A
- NDRA N/A
- Revenue This Year
- PCSA N/A
- NDRA N/A
- Revenue Next Year
- PCSA N/A
- NDRA N/A
- P/E Ratio
- PCSA N/A
- NDRA N/A
- Revenue Growth
- PCSA N/A
- NDRA N/A
- 52 Week Low
- PCSA $0.15
- NDRA $2.90
- 52 Week High
- PCSA $1.50
- NDRA $22.68
- Technical
- Relative Strength Index (RSI)
- PCSA 34.36
- NDRA 40.33
- Support Level
- PCSA $0.16
- NDRA $4.06
- Resistance Level
- PCSA $0.23
- NDRA $4.69
- Average True Range (ATR)
- PCSA 0.02
- NDRA 0.31
- MACD
- PCSA -0.00
- NDRA 0.03
- Stochastic Oscillator
- PCSA 26.71
- NDRA 21.04
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
About NDRA ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI at the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.